BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii Infection: Beyond 2018. Front Microbiol 2018;9:2271. [PMID: 30319580 DOI: 10.3389/fmicb.2018.02271] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Bachoura A, Zelouf DS. Mycobacterial Infections in the Hand and Wrist. Hand Clinics 2020;36:387-96. [DOI: 10.1016/j.hcl.2020.03.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hegde P, Boshoff HIM, Rusman Y, Aragaw WW, Salomon CE, Dick T, Aldrich CC. Reinvestigation of the structure-activity relationships of isoniazid. Tuberculosis (Edinb) 2021;129:102100. [PMID: 34116482 DOI: 10.1016/j.tube.2021.102100] [Reference Citation Analysis]
3 Rampacci E, Stefanetti V, Passamonti F, Henao-Tamayo M. Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research. Pathogens 2020;9:E641. [PMID: 32781698 DOI: 10.3390/pathogens9080641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Huang HL, Lu PL, Lee CH, Chong IW. Treatment of pulmonary disease caused by Mycobacterium kansasii. J Formos Med Assoc 2020;119 Suppl 1:S51-7. [PMID: 32505588 DOI: 10.1016/j.jfma.2020.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ma Z, Caldas Nogueira ML, Marchi-Salvador DP, Davidson VL. Correlation of Conservation of Sequence and Structures of Mycobacterial Hemerythrin-like Proteins with Evolutionary Relationship and Host Pathogenicity. ACS Omega 2020;5:23385-92. [PMID: 32954191 DOI: 10.1021/acsomega.0c03338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kwon YS, Daley CL, Koh WJ. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. Expert Rev Respir Med 2019;13:851-61. [PMID: 31256694 DOI: 10.1080/17476348.2019.1638765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Okuno H, Tanaka H, Hagiya H, Yoshida H, Hamaguchi S, Hori Y, Morii E, Hamada K, Yoshikawa H, Tomono K. Mycobacterium kansasii arthritis of the elbow in an immunocompetent patient with a suspected soft-tissue tumor. J Infect Chemother 2020;26:261-4. [PMID: 31427201 DOI: 10.1016/j.jiac.2019.07.015] [Reference Citation Analysis]
8 Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, Temesgen Z. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis 2021;24:100244. [PMID: 34036184 DOI: 10.1016/j.jctube.2021.100244] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Shen Y, Li Y, Li H, Liu Q, Dong H, Wang B, Ye B, Lin S, Shen Y, Wu D. Diagnosing MonoMAC Syndrome in GATA2 Germline Mutated Myelodysplastic Syndrome via Next-Generation Sequencing in a Patient with Refractory and Complex Infection: Case Report and Literature Review. Infect Drug Resist 2021;14:1311-7. [PMID: 33854343 DOI: 10.2147/IDR.S305825] [Reference Citation Analysis]
10 Moon SM, Choe J, Jhun BW, Jeon K, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Respir Med 2019;148:37-42. [PMID: 30827472 DOI: 10.1016/j.rmed.2019.01.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Khan O, Chaudary N. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults. Drug Des Devel Ther 2020;14:2287-94. [PMID: 32606598 DOI: 10.2147/DDDT.S146111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res 2020;152:185-226. [PMID: 33107481 DOI: 10.4103/ijmr.IJMR_902_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]